David Johnson, Sales and Marketing Director at 3P Innovation, gives an overview of the new GMP Cyrovial Filling Platform.
Part of the ‘Discover Range,’ the innovative device aims to automate the crucial process of filling cryovials with cell and gene therapy products, ensuring unprecedented levels of sterility and consistency. The CryoFil incorporates advanced technologies, including intelligent closed-loop filling, 100% weight verification, and a low-shear pump, minimizing cell damage and optimizing filling efficiency. The platform also facilitates automated cryovial placement into racks for swift transfer to controlled rate freezers, reducing contamination risks.
The CryoFil offers benefits such as unprecedented sterility assurance, 100% in-process checks, maximized cell yield, precision and accuracy, compact versatility, and compliance with CFR 21 part 11 regulations. This innovation further solidifies 3P Innovation’s commitment to supporting early-stage drug development activities in the cell and gene therapy sector. The company plans to showcase the CryoFil at Advanced Therapies Week 2024, reinforcing its dedication to providing tools and technologies for advancing life-saving therapies.
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.